Search results for " Time Factors"

showing 10 items of 148 documents

Molecular phylogeny of the extinct giant deer, Megaloceros giganteus.

2006

a Centre de Genetique Moleculaire et Cellulaire (CGMC), CNRS UMR 5534, Universite Claude Bernard Lyon 1, Villeurbanne, France b Laboratoire d’Anthropologie des Populations du Passe, CNRS UMR 5199 PACEA, Universite Bordeaux 1, Talence, France c UCD School of Biology and Environmental Science, UCD, BelWeld, Dublin 4, Ireland d Laboratoire d’Ecologie des Hydrosystemes Fluviaux, CNRS UMR 5023, Universite Claude Bernard Lyon 1, Villeurbanne, France e Biogeosciences-Dijon, CNRS UMR 5561, Universite de Bourgogne, Centre des Sciences de la Terre, Dijon, France f Department of Palaeontology, Royal Belgian Institute of Natural Sciences, Brussels, Belgium g Department of Biology, University College Lo…

0106 biological sciencesTime FactorsMESH: GeographyMESH: Base Sequence[SDV.BID.SPT]Life Sciences [q-bio]/Biodiversity/Systematics Phylogenetics and taxonomy01 natural sciencesMESH: FossilsMESH : BiodiversityMESH: AnimalsMESH: PhylogenyGiant deerPhylogenyComputingMilieux_MISCELLANEOUS[ SDU.STU.PG ] Sciences of the Universe [physics]/Earth Sciences/Paleontology0303 health sciencesbiologyAncient DNAGeographyEcologymtDNAFossils[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]MegalocerosMESH : GeographyClaude bernardBiodiversityMESH : Deer[ SDV.GEN.GPO ] Life Sciences [q-bio]/Genetics/Populations and Evolution [q-bio.PE][SDU.STU.PG]Sciences of the Universe [physics]/Earth Sciences/PaleontologyMESH : Time Factors[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]MESH: Deer010603 evolutionary biologyMESH: BiodiversityQuaternary03 medical and health sciencesGeneticsAnimals14. Life underwaterMolecular BiologyEcology Evolution Behavior and Systematics030304 developmental biologyBase SequenceDeerMESH: Time FactorsMESH : Phylogenybiology.organism_classificationMESH : FossilsMESH : Base SequenceMESH : AnimalsHumanities[ SDV.BID.SPT ] Life Sciences [q-bio]/Biodiversity/Systematics Phylogenetics and taxonomy
researchProduct

Medium-size droplets of methyl ricinoleate are reduced by cell-surface activity in the gamma-decalactone production by Yarrowia lipolytica.

2000

International audience; Size of methyl ricinoleate droplets during biotransformation into gamma-decalactone by Yarrowia lipolytica was measured in both homogenized and non-homogenized media. In non-homogenized but shaken medium, droplets had an average volume surface diameter d32 of 2.5 microm whereas it was 0.7 microm in homogenized and shaken medium. But as soon as yeast cells were inoculated, both diameters became similar at about 0.7 microm and did not vary significantly until the end of the culture. The growth of Y. lipolytica in both media was very similar except for the lag phase which was lowered in homogenized medium conditions.

0106 biological sciences[SDV.BIO]Life Sciences [q-bio]/BiotechnologyTime FactorsCell01 natural sciencesApplied Microbiology and BiotechnologyLactonesBiotransformationMESH : Particle SizeYeastsMESH: Microscopy Confocal[INFO.INFO-BT]Computer Science [cs]/BiotechnologyComputingMilieux_MISCELLANEOUSBiotransformation0303 health sciencesMicroscopyMicroscopy ConfocalbiologyMESH: YeastsMESH : Lactones[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologymedicine.anatomical_structureBiochemistryConfocalSURFACE ACTIVERicinoleic Acids[ INFO.INFO-BT ] Computer Science [cs]/BiotechnologyMESH: LactonesMESH : Time Factors03 medical and health sciencesMESH : Biotransformation010608 biotechnologymedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular Biology[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMESH: Particle SizeParticle SizeMESH : Microscopy Confocal[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyMethyl ricinoleateMESH: BiotransformationMESH : YeastsChromatography030306 microbiologyMESH: Time Factors[ SDV.BIO ] Life Sciences [q-bio]/BiotechnologyYarrowiabiology.organism_classificationYeastMESH: Ricinoleic AcidsCulture Media[SDV.BIO] Life Sciences [q-bio]/Biotechnology[INFO.INFO-BT] Computer Science [cs]/BiotechnologyMESH : Ricinoleic AcidsMESH: Culture MediaMESH : Culture Media
researchProduct

Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells

2017

Abstract Thyroid carcinoma is generally associated with good prognosis, but no effective treatments are currently available for aggressive forms not cured by standard therapy. To find novel therapeutic targets for this tumor type, we had previously performed a siRNA-based functional screening to identify genes essential for sustaining the oncogenic phenotype of thyroid tumor cells, but not required to the same extent for the viability of normal cells (non-oncogene addiction paradigm). Among those, we found the coatomer protein complex ζ1 (COPZ1) gene, which is involved in intracellular traffic, autophagy and lipid homeostasis. In this paper, we investigated the mechanisms through which COPZ…

0301 basic medicineCancer ResearchTime FactorsCOPZ1ApoptosisCOPZ1Thyroid cancerThyroid NeoplasmThyroidRNAi TherapeuticCell death; COPZ1; Non-oncogene addiction; Thyroid carcinoma; Animals; Apoptosis; Autophagy; Cell Line Tumor; Cell Survival; Coatomer Protein; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation Neoplastic; Humans; Mice Nude; RNA Interference; Signal Transduction; Thyroid Neoplasms; Time Factors; Transfection; Tumor Burden; Unfolded Protein Response; Xenograft Model Antitumor Assays; RNAi Therapeutics; Oncology; Cancer ResearchEndoplasmic Reticulum StressOncogene AddictionTumor BurdenGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyFemaleRNA InterferenceNon-oncogene addictionHumanSignal TransductionCell deathProgrammed cell deathXenograft Model Antitumor AssayTime FactorCell SurvivalMice NudeBiologyTransfectionCoatomer ProteinThyroid carcinomaThyroid carcinoma03 medical and health sciencesCell Line TumorAutophagymedicineAnimalsHumansThyroid NeoplasmsEndoplasmic Reticulum StreAnimalAutophagyApoptosimedicine.diseaseXenograft Model Antitumor AssaysRNAi Therapeutics030104 developmental biologyImmunologyUnfolded Protein ResponseCancer researchUnfolded protein response
researchProduct

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Withou…

2016

International audience; BACKGROUND & AIMS: Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).METHODS: Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and …

0301 basic medicineLiver CirrhosisMaleTime FactorsIntention to Treat Analysi[SDV]Life Sciences [q-bio]BiopsyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologySeverity of Illness IndexChalcone0302 clinical medicineChalconesNon-alcoholic Fatty Liver DiseaseGastrointestinal AgentNonalcoholic fatty liver diseasePropionateMedicine and Health SciencesOdds RatioMedicineGlucose homeostasisVITAMIN-Eeducation.field_of_studyGastrointestinal agentFatty liverRemission InductionGastroenterologyMiddle Aged3. Good healthIntention to Treat AnalysisPPARDEuropeTreatment OutcomeLiverACIDPIOGLITAZONE030211 gastroenterology & hepatologyFemalePPARAHumanSignal TransductionAdultCLINICAL-OUTCOMESmedicine.medical_specialtyLogistic ModelTime FactorLiver CirrhosiPopulationfatty liver; NAFLD; PPARA; PPARD; Adult; Biomarkers; Biopsy; Chalcones; Double-Blind Method; Europe; Female; Gastrointestinal Agents; Humans; Intention to Treat Analysis; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; PPAR alpha; PPAR gamma; Propionates; Remission Induction; Severity of Illness Index; Signal Transduction; Time Factors; Treatment Outcome; United States; GastroenterologyPlacebo03 medical and health sciencesDouble-Blind MethodGastrointestinal AgentsInternal medicineNAFLDHumansPPAR alphaeducationFATTY LIVER-DISEASEfatty liverHepatologybusiness.industryBiomarkerAMERICAN ASSOCIATIONOdds ratiomedicine.diseaseConfidence intervalUnited StatesPPAR gammaRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyEndocrinologyLogistic ModelsHuman medicinePropionatesbusinessBiomarkers
researchProduct

Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project

2020

The latest European Guidelines of Arterial Hypertension have officially introduced uric acid evaluation among the cardiovascular risk factors that should be evaluated in order to stratify patient's risk. In fact, it has been extensively evaluated and demonstrated to be an independent predictor not only of all-cause and cardiovascular mortality, but also of myocardial infraction, stroke and heart failure. Despite the large number of studies on this topic, an important open question that still need to be answered is the identification of a cardiovascular uric acid cut-off value. The actual hyperuricemia cut-off (> 6 mg/dL in women and 7 mg/dL in men) is principally based on the saturation …

0301 basic medicineMaleTime FactorsDiseaseUric acid.chemistry.chemical_compound0302 clinical medicineRisk FactorsUric Acid Cardiovascular events epidemiologyEpidemiologyMulticenter Studies as TopicHyperuricemiaStrokeCardiovascular events; Cardiovascular mortality; Uric acid; URRAHMiddle AgedPrognosisObservational Studies as TopicItalyCardiovascular DiseasesResearch DesignFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyCardiovascular mortalityUric acid · Cardiovascular mortality · Cardiovascular events · URRAHContext (language use)Cardiovascular eventHyperuricemiaRisk AssessmentCardiovascular events03 medical and health sciencesURRAHcardiovascular events; cardiovascular mortality; urrah; uric acidPharmacotherapyInternal medicineInternal MedicinemedicineHumansAgedRetrospective Studiesbusiness.industrymedicine.disease030104 developmental biologychemistryHeart failureUric acidbusinessUric acid030217 neurology & neurosurgeryCardiovascular events; Cardiovascular mortality; Uric acid; URRAH; Adult; Aged; Biomarkers; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Italy; Male; Middle Aged; Multicenter Studies as Topic; Observational Studies as Topic; Prognosis; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Uric AcidBiomarkers
researchProduct

Retinoblastoma Is Characterized by a Cold, CD8+ Cell Poor, PD-L1- Microenvironment, Which Turns Into Hot, CD8+ Cell Rich, PD-L1+ After Chemotherapy.

2021

Purpose To investigate the impact of chemotherapy (CHT) on human retinoblastoma (RB) tumor microenvironment (TME). Cases and Methods Ninety-four RBs were studied, including 44 primary RBs treated by upfront surgery (Group 1) and 50 primary RBs enucleated after CHT (CHT), either intra-arterial (IAC; Group 2, 33 cases) or systemic (S-CHT; Group 3, 17 cases). Conventional and multiplexed immunohistochemistry were performed to make quantitative comparisons among the three groups, for the following parameters: tumor-infiltrating inflammatory cells (TI-ICs); programmed cell death protein 1 (PD-1) positive TI-ICs; Ki67 proliferation index; gliosis; PD-1 ligand (PD-L1) protein expression; vessel nu…

0301 basic medicineMaleTime FactorsProliferation indexRetinal NeoplasmsProgrammed Cell Death 1 Receptorretinoblastoma; tumor microenvironment; chemotherapy; PD-1/PD-L1; multiplexed immunohistochemistry; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Child Preschool; Female; Follow-Up Studies; Humans; Immunohistochemistry; Infant; Infant Newborn; Lymphocytes Tumor-Infiltrating; Male; Programmed Cell Death 1 Receptor; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Time Factors; Tumor MicroenvironmentCD8-Positive T-LymphocyteschemotherapyPD-1/PD-L1B7-H1 AntigenRetina03 medical and health sciencesretinoblastoma; tumor microenvironment chemotherapy PD-1/PD-L1 multiplexed immunohistochemistry0302 clinical medicineLymphocytes Tumor-InfiltratingPD-L1medicineTumor MicroenvironmentHumansLymphocytesTumor-InfiltratingChildPreschoolAnaplasiaRetrospective StudiesTumor microenvironmentbiologyRetinoblastomaChemistryInfant NewbornRetinoblastomaInfantGeneral Medicinemultiplexed immunohistochemistrymedicine.diseaseNewbornChemotherapy regimenImmunohistochemistry030104 developmental biologyGliosis030220 oncology & carcinogenesisChild Preschoolbiology.proteinCancer researchFemalemedicine.symptomCD8Follow-Up StudiesInvestigative ophthalmologyvisual science
researchProduct

Factors affecting basket catheter detection of real and phantom rotors in the atria: A computational study

2018

[EN] Anatomically based procedures to ablate atrial fibrillation (AF) are often successful in terminating paroxysmal AF. However, the ability to terminate persistent AF remains disappointing. New mechanistic approaches use multiple-electrode basket catheter mapping to localize and target AF drivers in the form of rotors but significant concerns remain about their accuracy. We aimed to evaluate how electrode-endocardium distance, far-field sources and inter-electrode distance affect the accuracy of localizing rotors. Sustained rotor activation of the atria was simulated numerically and mapped using a virtual basket catheter with varying electrode densities placed at different positions withi…

Ablation TechniquesNormalization propertyTime FactorsPhysiologymedicine.medical_treatmentAction Potentials02 engineering and technology030204 cardiovascular system & hematologylaw.invention0302 clinical medicineModelslawHeart RateMedicine and Health SciencesMapping cathetersCardiac Atrialcsh:QH301-705.5Numerical AnalysisEcologyRotor (electric)HeartAblationElectrophysiologyComputational Theory and Mathematicsmedicine.veinModeling and SimulationRotorsPhysical SciencesInferior Vena CavaEngineering and TechnologyAnatomyBasket catheterArrhythmiaInterpolationResearch ArticleBiotechnologyMaterials scienceCatheters0206 medical engineeringPhase (waves)CardiologyInferior vena cavaModels BiologicalMembrane PotentialImaging phantomVeinsTECNOLOGIA ELECTRONICA03 medical and health sciencesCellular and Molecular NeuroscienceAblation Techniques; Action Potentials; Atrial Fibrillation; Computational Biology; Computer Simulation; Heart Atria; Heart Conduction System; Heart Rate; Humans; Models Biological; Time FactorsHeart Conduction SystemPhase analysisGeneticsmedicineHumansComputer SimulationHeart AtriaMolecular BiologyEcology Evolution Behavior and SystematicsMechanical EngineeringComputational BiologyBiology and Life SciencesBiological020601 biomedical engineeringAtrial fibrillationInterpolationlcsh:Biology (General)Cardiovascular AnatomyBlood VesselsMedical Devices and EquipmentMathematicsBiomedical engineeringEndocardium
researchProduct

[Prevalence of pericardial effusion in subjects with rheumatoid arthritis: an echocardiographic study].

1994

We used echocardiography to determine the prevalence of pericardial effusion in rheumatoid arthritis (RA) patients without cardiac systems and compared our results to those obtained in a control group of age-matched subjects. Thirty-six patients with RA (6 men, 30 women; mean age 51 +/- 11 years) were selected from a patient population in treatment at our outpatient Rheumatology Clinic. None of the patients had any symptoms of cardiac disease, and all patients with signs and/or systems of extracardiac disease were excluded from the study. The control group consisted of 60 volunteers (mean age 51 +/- 12 years) randomly selected from a larger group of subjects with neither symptoms, signs and…

AdultArthritis RheumatoidMaleAdult Arthritis Rheumatoid/complications* Cross-Sectional Studies Echocardiography* Female Humans Male Middle Aged Pericardial Effusion/diagnosis Pericardial Effusion/epidemiology* Pericardial Effusion/etiology Time FactorsSettore MED/09 - Medicina InternaCross-Sectional StudiesTime FactorsEchocardiographyHumansFemaleMiddle AgedSettore MED/11 - Malattie Dell'Apparato CardiovascolarePericardial EffusionAnnali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna
researchProduct

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Der…

2021

Abstract Aim Immune checkpoint inhibition (ICI) triggers immune-related adverse events (irAEs). The relevance of lipase elevation remains unclear. Patients and methods Skin cancer patients with newly detected serum lipase elevation (at least twofold upper normal limit) or newly diagnosed type I diabetes mellitus upon ICI therapy were retrospectively collected at 14 German skin cancer centres. Results We identified 68 patients with lipase elevation occurring after a median time of 19 (range 1–181) weeks on ICI, 15 (22%) thereof had symptoms consistent with pancreatitis. Forty-seven patients (73%) had other irAE, mainly colitis. Discontinuation (n = 24, 35%) or interruption (n = 26, 38%) of I…

AdultBlood GlucoseMale0301 basic medicineCancer Researchmedicine.medical_specialtySkin NeoplasmsTime FactorsMedizinGastroenterologyThyroiditisYoung Adult03 medical and health sciences0302 clinical medicinePredictive Value of TestsGermanyInternal medicineDiabetes mellitusmedicineHumansLipaseAdverse effectImmune Checkpoint InhibitorsMelanomaAgedRetrospective StudiesAged 80 and overType 1 diabetesbiologybusiness.industryDiabetes; Diabetes mellitus; Immune checkpoint inhibitors; Immune-related adverse events; Ipilimumab; Lipase; Nivolumab; Pancreatitis; PD-1 inhibitor; Pembrolizumab; Adult; Aged; Aged 80 and over; Biomarkers; Blood Glucose; Diabetes Mellitus Type 1; Exocrine Pancreatic Insufficiency; Female; Germany; Humans; Immune Checkpoint Inhibitors; Lipase; Male; Melanoma; Middle Aged; Pancreatitis; Predictive Value of Tests; Retrospective Studies; Skin Neoplasms; Time Factors; Treatment Outcome; Up-Regulation; Young AdultLipaseMiddle Agedmedicine.diseaseUp-RegulationKetoacidosisDiabetes Mellitus Type 1Treatment Outcome030104 developmental biologyPancreatitisOncology030220 oncology & carcinogenesisbiology.proteinPancreatitisExocrine Pancreatic InsufficiencyFemaleSkin cancerbusinessBiomarkersEuropean Journal of Cancer
researchProduct

Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

2021

Abstract Background The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care, with particular regard to cardiovascular risk factors. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD Annals initiative. Patients with T2D were stratified by cardiovascular risk. General descriptive indicators, measures of intermediate outcomes, inten…

AdultBlood GlucoseMalelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismType 2 diabetesIncretinsRisk AssessmentDiabetes mellitusInternal medicinemedicineElectronic Health RecordsHumansHypoglycemic AgentsMedical prescriptionSodium-Glucose Transporter 2 InhibitorsOriginal InvestigationAgedQuality Indicators Health CareRetrospective StudiesAngiologyCardiovascular risk Humans Hypoglycemic Agents Incretins Italy Male Middle Aged Retrospective Studies Risk Assessment Sodium-Glucose Transporter 2 Inhibitors Time Factors Treatment Outcome Quality Indicators Health Care Quality of care Type 2 diabetes Adult Aged Aged 80 and over Biomarkers Blood Glucose Cardiovascular Diseases Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Heart Disease Risk Factors Female Electronic Health RecordsAged 80 and overDipeptidyl-Peptidase IV Inhibitorsbusiness.industryMedical recordQuality of careType 2 diabetesRetrospective cohort studyMiddle AgedCardiovascular riskmedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2ItalyCardiovascular DiseasesHeart Disease Risk Factorslcsh:RC666-701AlbuminuriaFemaleObservational studymedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular Diabetology
researchProduct